Takeda Oncology
Gustavo Gurrieri is a seasoned healthcare market research professional with extensive experience in oncology. Currently serving as the Head of Global Oncology Strategic Market Research at Takeda Oncology since April 2018, Gustavo has previously held multiple roles at Bayer HealthCare, including Head of US Market Intelligence Oncology and Deputy Director of Market Intelligence. Prior experience also includes positions at Sanofi, where roles spanned from Sr. Manager in Oncology New Products Market Research to Director of Market Access & Business Development MR, and earlier roles at GfK and the University of Connecticut. Gustavo holds a Master’s degree in Political Science with a focus on Survey Research from the University of Connecticut and a Bachelor’s degree in Anthropology from Universidad de Chile.
This person is not in any teams
This person is not in any offices
Takeda Oncology
21 followers
In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. AtTakeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer.They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.